ImetelChat

Per presentation - As of August 2017, OS has not been achieved in MF test groups.

It is interesting to note that during ASH 2016, Janssen presented the database of information that they had spent the time & resources to compile:
Abstract #4769
Characterization of disease, treatment patterns, and outcomes of patients with myelofibrosis: analysis of 2 United States commercial claims databases

Seems as if they were one step ahead, as they can use this database to characterize the OS for these patients.

Actually I think it will be more than one step....

Ryan, yes, its is clear on the face of it that since there is no control group (would that there were!--we would be done by now), that some other yard stick for efficacy must be utilized and J and J wanted to establish that this mile stone would be survival (OS 7 months in R/R according to this study). Had the MD Anderson study (a much smaller study) not been available (OS in R/R 14 months) the bar might not have been raised higher and we might be done by now. But clearly we are not done and OS has not been reached but some standard that might be acknowledged by FDA has been established by these two studies. For these reasons we can only wait until OS is reached and hope the blow the standards established out of the water. In the meantime it sure would be nice to see some surrogate end points presented at ASH to confirm things are on the right track. bp